KIDNEY - CONTROL OF HOMEOSTASIS - Siwss National Centre of Competence in Research open the menu close the menu

News & Events

See the latest news from the NCCR Kidney.CH below.

The NCCR also regularly organizes educational, networking and outreaching events. Information on upcoming and past events of the NCCR Kidney.CH and other organizers can be found below. Please use the drop-down menu to confine your search.

  • News


    • 16 December 2020

      NCCR-sponsored IPAHK+ trial gets "POSH"

      An elegant new sub-study examines the effects of potassium supplementation on blood pressure in patients with hypokalemia.

      more Details

    • 2 November 2020

      Prof. Sophie de Seigneux wins Stern-Gattiker prize

      The Swiss Academy of Medical Sciences (SAMS) recently announced the winners of the 2020 Stern-Gattiker Prize, a biennial award recognizing outstanding women in academia. The NCCR's own Sophie de Seigneux was one of two women recognized this year.

      more Details

    • 12 October 2020

      Electrophysiology Facility launches

      In a joint effort of the Department of Molecular Life Sciences of UZH and the Institute of Anatomy, as well as the Clinic of Endocrinology, Diabetology and Clinical Nutrition from the USZ and the National Center of Competence in Research (NCCR) Kidney.CH, we have launched the Electrophysiology Facility (e-phac).

      more Details

    • 9 September 2020

      Cancer drug can rebalance kidney function in a devastating genetic disease

      Researchers at the University of Cambridge and the University of Zurich, including NCCR member Olivier Devuyst, have discovered that a drug newly approved for cancer improves kidney dysfunction in a mouse model of Dent disease 2 and Lowe syndrome.

      more Details

    • 2 July 2020

      NCCR member contributes to Science paper on uromodulin

      NCCR scientist & uromodulin expert Olivier Devuyst contributed to this Science paper on how #uromodulin helps fight off urinary tract infections.

      more Details

    • later entries
  • All Events

    All Events

  • Retreat 2021

    Retreat 2021

  • Symposium 2021

    Symposium 2021


16 December 2020

NCCR-sponsored IPAHK+ trial gets "POSH"

An elegant new sub-study examines the effects of potassium supplementation on blood pressure in patients with hypokalemia.

The IPAHK+ (“Incidence of Primary Aldosteronism in Patients with Hypokalemia”) study was launched by the Zurich University Hospital's Endocrinology Clinic in October 2019, with the goal of investigate the incidence of primary hyperaldosteronism in a hypokalemic population. Since then, a hypokalemia registry specially set up for this purpose, which records all outpatients at the University Hospital Zurich with hypokalemia ≤ 3.0 mmol/l, has been growing continuously. As of today, 516 entries have been reported. The evaluation of the first 100 reported patients is currently underway and a corresponding publication is expected in spring 2021.

In parallel, an exciting new sub-study has been developed called “POSH”. On its own, the name POSH serves as an acronym for “effects of POtassium Supplementation on blood pressure in patients with Hypokalemia”, a phrase which briefly describes the trial. However, the name was also aptly chosen because the study is charmingly elegant in its design, procedures and scientific question.

The background to this trial is the identification of potassium as an important regulator of blood pressure and thus its implementation as a therapeutic modulator of arterial hypertension. However, the underlying mechanisms that translate into inter-individual variability of potassium dependent decrease in blood pressure have remained largely unclear. The “POSH” study is a prospective interventional trial examining the short-term effects of a one-week oral potassium substitution in hypertensive patients with severe hypokalemia (≤ 2.6 mmol/l). The main focus of the study is on the intra- and inter-individual effects of potassium supplementation on blood pressure and the regulation of the renin-angiotensin-aldosterone system (RAAS). The study will further include a deep phenotyping approach by inclusion of plasma and urine steroid profiles and targeted plasma metabolomics and urinary exosomes.

The sub-study is expected to uncover potential mechanisms involved in blood pressure pathophysiology and control. Furthermore, the multilayer omics-based characterization of “potassium-sensitive” and “potassium-resistant” individuals in terms of blood pressure reduction might help to distinguish between those subpopulations. The POSH trial thus represents a sophisticated approach towards personalized treatment of arterial hypertension based on the individual potassium response.

Find more information about the IPAHK+ study here: